SAN FRANCISCO, Aug. 29, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that it will participate in the following
investor conferences in September:
- Citi's 13th Annual Biotech Conference
Matthew R. Patterson, Chief Executive
Officer
Format: 1x1 Investor Meetings
Wednesday, September 5, 2018
Boston, Massachusetts
- Morgan Stanley 16th Annual Global Healthcare
Conference
Natalie Holles,
President and Chief Operating Officer
Format: Fireside Chat
Wednesday, September 12, 2018, at
8:10am ET
New York, New York
To access a live webcast of the Morgan Stanley Global Healthcare
Conference fireside chat, please visit the Events &
Presentations page within the Investors + Media section of the
Audentes website. A replay of the live webcast will be
available on the Audentes website for approximately 30 days
following the conference.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product
candidates, AT132 for the treatment of X-linked myotubular myopathy
(XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-upcoming-investor-conferences-300703682.html
SOURCE Audentes Therapeutics, Inc.